Nothing Special   »   [go: up one dir, main page]

FR2794977B1 - Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention - Google Patents

Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention

Info

Publication number
FR2794977B1
FR2794977B1 FR9907736A FR9907736A FR2794977B1 FR 2794977 B1 FR2794977 B1 FR 2794977B1 FR 9907736 A FR9907736 A FR 9907736A FR 9907736 A FR9907736 A FR 9907736A FR 2794977 B1 FR2794977 B1 FR 2794977B1
Authority
FR
France
Prior art keywords
hla
soluble forms
obtaining
treatment
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9907736A
Other languages
English (en)
Other versions
FR2794977A1 (fr
Inventor
Selim Aractingi
Edgardo Delfino Carosella
Jean Dausset
Daher Iman Khalil
Philippe Moreau
Pascale Paul
Freiss Nathalie Rouas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9907736A priority Critical patent/FR2794977B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to DK00951595T priority patent/DK1189627T3/da
Priority to CA2377519A priority patent/CA2377519C/fr
Priority to AT00951595T priority patent/ATE251911T1/de
Priority to JP2001504400A priority patent/JP2003508351A/ja
Priority to PCT/FR2000/001670 priority patent/WO2000078337A1/fr
Priority to ES00951595T priority patent/ES2206286T3/es
Priority to EP00951595A priority patent/EP1189627B1/fr
Priority to DE60005952T priority patent/DE60005952T8/de
Priority to IL14712300A priority patent/IL147123A0/xx
Publication of FR2794977A1 publication Critical patent/FR2794977A1/fr
Priority to IL147123A priority patent/IL147123A/en
Application granted granted Critical
Publication of FR2794977B1 publication Critical patent/FR2794977B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR9907736A 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention Expired - Fee Related FR2794977B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
DE60005952T DE60005952T8 (de) 1999-06-18 2000-06-16 Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
AT00951595T ATE251911T1 (de) 1999-06-18 2000-06-16 Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
JP2001504400A JP2003508351A (ja) 1999-06-18 2000-06-16 炎症性皮膚病理を処置するためのｈｌａ−ｇの可溶性形態を含む組成物
PCT/FR2000/001670 WO2000078337A1 (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau
ES00951595T ES2206286T3 (es) 1999-06-18 2000-06-16 Composciones que contienen formas solubles de hla-g en el tratamiento de patologias inflamatorias.
DK00951595T DK1189627T3 (da) 1999-06-18 2000-06-16 Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
CA2377519A CA2377519C (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau
IL14712300A IL147123A0 (en) 1999-06-18 2000-06-16 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
EP00951595A EP1189627B1 (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau
IL147123A IL147123A (en) 1999-06-18 2001-12-16 Use of compositions containing at least one soluble form of G – HLA for the preparation of a medicinal product for the treatment of inflammatory pathologies of the skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention

Publications (2)

Publication Number Publication Date
FR2794977A1 FR2794977A1 (fr) 2000-12-22
FR2794977B1 true FR2794977B1 (fr) 2003-10-31

Family

ID=9546968

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9907736A Expired - Fee Related FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention

Country Status (10)

Country Link
EP (1) EP1189627B1 (fr)
JP (1) JP2003508351A (fr)
AT (1) ATE251911T1 (fr)
CA (1) CA2377519C (fr)
DE (1) DE60005952T8 (fr)
DK (1) DK1189627T3 (fr)
ES (1) ES2206286T3 (fr)
FR (1) FR2794977B1 (fr)
IL (2) IL147123A0 (fr)
WO (1) WO2000078337A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
WO2007011044A1 (fr) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Composition pharmaceutique comprenant un dimere hla-g lie disulfide et procede de fabrication de ce dimere hla-g lie disulfide
JP5653620B2 (ja) 2006-11-15 2015-01-14 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 柔軟なポリウレタンフォームを製造する方法
EP2184297A1 (fr) * 2008-11-07 2010-05-12 Hla-G Technologies Polypeptides HLA-G et leurs utilisations pharmaceutiques
EP2184070A1 (fr) 2008-11-07 2010-05-12 Hla-G Technologies Protéines HLA-G et leurs utilisations pharmaceutiques
EP2264067A1 (fr) 2009-06-18 2010-12-22 Hla-G Technologies Multimères de HLA-G alpha 1 et leurs utilisations pharmaceutiques
JP5736368B2 (ja) 2009-06-25 2015-06-17 コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ’Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ 少なくとも２つのα３ドメインを含むＨＬＡ−Ｇの多量体ポリペプチド及び医薬としてのその使用
ES2606627T3 (es) * 2010-05-28 2017-03-24 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
JP2020521000A (ja) 2017-05-23 2020-07-16 ヴァレンティン ブリュッテル， 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
KR20220026586A (ko) 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
EP3994278A1 (fr) * 2019-07-05 2022-05-11 Intellexon GmbH Hla-h en médecine et diagnostic
WO2021260657A1 (fr) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
CA2213620A1 (fr) * 1995-04-07 1996-10-10 The Regents Of The University Of California Anticorps pour la detection de hla-g
CA2221687A1 (fr) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Recepteurs relies a la necrose des tumeurs, tr5
FR2760023B1 (fr) * 1997-02-21 2004-05-07 Commissariat Energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications

Also Published As

Publication number Publication date
ES2206286T3 (es) 2004-05-16
DK1189627T3 (da) 2004-02-16
EP1189627B1 (fr) 2003-10-15
DE60005952T8 (de) 2004-11-04
WO2000078337A1 (fr) 2000-12-28
EP1189627A1 (fr) 2002-03-27
FR2794977A1 (fr) 2000-12-22
CA2377519C (fr) 2011-09-27
JP2003508351A (ja) 2003-03-04
DE60005952D1 (de) 2003-11-20
IL147123A (en) 2010-06-30
DE60005952T2 (de) 2004-07-29
IL147123A0 (en) 2002-08-14
ATE251911T1 (de) 2003-11-15
CA2377519A1 (fr) 2000-12-28

Similar Documents

Publication Publication Date Title
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
EP1526132A3 (fr) Dérivés oxazolidinone substitués et leur utilisation comme inhibiteurs de facteur xa
MA24193A1 (fr) Procedes pour la preparation de conjugue peg-ifn alpha physiologiquement actif, et pour la preparation de compositions pharmaceutiques le contenant et leur utilisation
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
FR2754713B1 (fr) Utilisation de complexes pour la preparation de compositions pour le traitement des peaux sensibles, procede de preparation et compositions hypoallergeniques
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EP0796623A3 (fr) Préparation pharmaceutique pour le traitement des maladies de la coagulation sanguine
MA23744A1 (fr) Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisation
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60236639D1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
FR2794977B1 (fr) Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
FR2797186B1 (fr) Procede d'extraction d'un principe actif a partir de levures, notamment pour le traitement des rides, principe actif obtenu, compositions cosmetiques et traitement adaptes
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
TR200200278T2 (tr) Kalsilitik bileşimler
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
MA26648A1 (fr) Associations thérapeutiques pour le traitement de maladies osseuses, et procédé pour leur préparation.
TNSN00095A1 (fr) Benzolactames et thioamides cycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99104A1 (fr) 3 - cetoderives tricycliques de 6 - 0 - methylerythromycine, procede pour leur preparation et compositions pharmaceutiques les contenant
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060228